Category: carcinoid

8 Easy Steps to Sign Up for Carcinoid Cancer and Neuroendocrine Tumor Google Alerts

Do you want to get the latest news about carcinoid and other neuroendocrine tumors delivered directly to your email address? Are you interested in stories about carcinoid/NET survivors, research, clinical trials, blogs, physicians, or organizations? …

2nd World Congress on Ga-68, Molecular Imaging & Targeted Radionuclide Therapy

Chandigarh, India will be the site of the 2nd World Congress on Ga-68 (Generators and Novel Radiopharmaceuticals), Molecular Imaging (PET/CT), Targeted Radionuclide Therapy and Dosimetry:  On the Way to Personalized Medicine from February 28 through…

Treating Neuroendocrine Tumors: New Patent Awarded

Herbert Chen, MD, and Muthusamy Kunnimalaiyaan, Ph.D., of the University of Wisconsin School of Medicine and Public Health in Madison, have received a patent (8,338,482) for a “Modulating Notch1 Signaling Pathway for Treating Neuroendocrine…

Happy New Year from the Carcinoid Cancer Foundation

As 2012 draws to a close, the Carcinoid Cancer Foundation would like to thank each of you for your support.  This year has been especially exciting because of our work on the Worldwide NET Cancer Awareness Day Alliance, with Grace Goldstein, CCF’s Chief…

New Videos in Carcinoid Cancer Foundation 2012-2013 Series

Faces of Hope and Surgery and Treatment Options are the newest videos in the Carcinoid Cancer Foundation’s 2012-2013 series.  Awareness and education are the first critical components in the fight against carcinoid and NET (neuroendocrine …

10 Highlights of the Year 2012 for the Carcinoid and Neuroendocrine Tumor Community

As the Carcinoid Cancer Foundation looks back on the year 2012, there were many significant events and advances for the carcinoid and neuroendocrine tumor (NET) community.  Here are 10 of the year’s important stories:

1)       NET Cancer Day, November …

Lexicon Pharmaceuticals Begins Phase 3 Clinical Trial of Telotristat Etiprate in Patients with Carcinoid Syndrome

Patients with metastatic carcinoid syndrome will have the opportunity to participate in a new Phase 3 clinical trial of Lexicon Pharmaceutical’s telotristat etiprate (LX1032), an oral drug candidate designed to treat carcinoid syndrome by reducing…

Carcinoid Cancer Foundation Participates in #GivingTuesday

Help launch #GivingTuesday™!!  The Carcinoid Cancer Foundation is proud to participate in the first annual #GivingTuesday™ to be held on Tuesday, November 27, 2102. Charities, families, businesses and individuals are coming together to transform…

First U.S. Center to Enroll Patients in International, Multicenter Clinical Trial of Lu-177 Octreotate

Excel Diagnostics and Nuclear Oncology Center in Houston, Texas, is the first center in the United States to start recruiting patients in a multicenter randomized clinical trial of Lu-177 Octreotate in patients with progressive midgut carcinoid. …

Archived Neuroendocrine Tumor Webinar by Dr. Eric Liu Now Available

Dr. Eric H. Liu, Director of the Neuroendocrine Center and Director of Surgical Services at Vanderbilt University Medical Center in Tennessee, presented a live webinar on August 22, 2012 entitled Imaging of Neuroendocrine Tumors and Obstacles to Diagnosis.…